Scpharmaceuticals Inc (NASDAQ:SCPH) has been given an average broker rating score of 1.00 (Strong Buy) from the three brokers that cover the company, Zacks Investment Research reports. Three investment analysts have rated the stock with a strong buy recommendation.
Analysts have set a 1-year consensus price target of $23.33 for the company and are expecting that the company will post ($0.51) EPS for the current quarter, according to Zacks. Zacks has also assigned Scpharmaceuticals an industry rank of 163 out of 265 based on the ratings given to related companies.
A number of equities research analysts recently weighed in on the company. Zacks Investment Research cut Scpharmaceuticals from a “hold” rating to a “sell” rating in a research note on Wednesday, February 14th. Jefferies Group restated a “buy” rating and set a $26.00 price objective on shares of Scpharmaceuticals in a research note on Wednesday, March 21st.
Shares of NASDAQ SCPH traded down $0.56 during mid-day trading on Wednesday, reaching $10.19. 90,985 shares of the company were exchanged, compared to its average volume of 56,989. The company has a debt-to-equity ratio of 0.09, a current ratio of 24.12 and a quick ratio of 24.12. The stock has a market capitalization of $203.88 and a P/E ratio of -1.27. Scpharmaceuticals has a 1 year low of $10.12 and a 1 year high of $18.17.
Scpharmaceuticals (NASDAQ:SCPH) last issued its quarterly earnings data on Tuesday, March 20th. The company reported ($0.80) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.27). equities research analysts anticipate that Scpharmaceuticals will post -2.79 earnings per share for the current fiscal year.
scPharmaceuticals Inc, a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products. The company's under development products are for heart failure and infectious diseases that include Furoscix for the treatment of worsening or decompensated heart failure outside of the inpatient setting.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Scpharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Scpharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.